Top Stories

first_img Top Stories “It’s huge,” said head coach Bruce Arians. “Having such a good spring and fall camp, and then to lose him for that amount of time was tough. He’s another added dimension that we need.”Wide receiver Larry Fitzgerald said Housler creates problems for the opposing defense and that the whole offense will benefit from his presence.“Rob is one of the fastest tight ends in the game and he creates tremendous matchup issues up the seams,” Fitzgerald added. “Having that added dimension is only going to make us stronger. I’m really happy to have him back.”Housler, who’s in his third year out of Florida Atlantic University, led Cardinals’ tight ends in receptions in 2012 with 45 that resulted in 417 yards. At 6-foot-5 and 250 pounds, he ran the 40-yard-dash in 4.46 seconds at the 2011 NFL Combine. Another person that is excited for Housler’s return is offensive coordinator Harold Goodwin, who now gets to use the tight end’s speed and size in the team’s game plan. “Obviously he’s going to be a huge plus for us having him out there,” Goodwin said. “They’ve got to match up against him. He’s a tight end with speed, wide receiver type speed, so defensively they’re going to have to do something. If they don’t, he’s going to have a huge day.” Former Cardinals kicker Phil Dawson retires The Saints have defended well against tight ends so far this season, allowing just four receptions for 70 yards, so it appears Housler may have his work cut out for him. Grace expects Greinke trade to have emotional impact Comments   Share   Derrick Hall satisfied with D-backs’ buying and selling Though the Arizona Cardinals offense has already shown improvement over last year, they’re excited to add back tight end Rob Housler, who they feel will help take them to the next level.Housler was penciled in as the starter at TE before he suffered a high ankle sprain in the team’s third preseason game. He had an impressive camp leading up to the injury and the Cardinals had high expectations for him this season. The 5: Takeaways from the Coyotes’ introduction of Alex Meruelolast_img read more

admin August 11, 2019 dsvvnr Leave a Comment

Read More

European Commission approves Pfizers first oncology biosimilar

first_img Source:https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_european_approval_for_oncology_biosimilar_trazimera_trastuzumab Jul 31 2018Pfizer Inc. today announced the European Commission (EC) has approved TRAZIMERA™, a biosimilar to Herceptin®  (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.  This approval follows the recommendation from the Committee for Medicinal Products for Human Use in May 2018.Related StoriesBacteria in the birth canal linked to lower risk of ovarian cancerLiving with advanced breast cancerFDA grants accelerated approval to new treatment for refractory multiple myeloma”TRAZIMERA has the potential to help many patients with HER2 overexpressing cancers, such as breast and gastric, which can correlate with poor outcomes and aggressive disease,” said Professor Diana Lüftner, Charité Campus Benjamin Franklin and Member of the Presidency of the German Society of Hematology and Medical Oncology. “Today’s approval will help enable greater access for patients and physicians across Europe, without compromising on quality, efficacy and safety.”Richard Blackburn, Global President, Pfizer Essential Health Europe, Africa/Middle East and Biosimilars said “The approval of TRAZIMERA, Pfizer’s first oncology biosimilar, is another significant step in our quest to introduce more treatment options for patients in Europe. Pfizer is investing in developing and launching a range of biosimilars which can help to reduce healthcare costs and increase patient access to important medicines.”last_img read more

admin July 20, 2019 fkvuuq Leave a Comment

Read More